[8-K] Forward Industries Inc-N Y Reports Material Event

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) – Form 4 insider filing

EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory “sell-to-cover” to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.

Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.

The event does not materially alter management’s economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.

Positive

• Executive retains 106,062 shares, indicating continued alignment with shareholder interests.
• Transaction was pre-programmed and tax-driven, reducing concerns about opportunistic insider selling.

Negative

• Even administrative insider sales can create superficial bearish headlines that may pressure short-term sentiment.

Insights

Securities Analyst

TL;DR: Routine sell-to-cover, neutral signal.

The CFO’s 7,462-share sale—only ~7% of his 106k-share stake—was required to cover taxes on vested RSUs, a common practice that avoids out-of-pocket tax payments. Because the shares were disposed automatically and promptly disclosed, the transaction offers little insight into management’s outlook on NTLA fundamentals. Insider ownership remains significant, supporting alignment with shareholders. I regard the filing as operationally neutral with no valuation impact.

Corporate Governance Expert

TL;DR: Compliant disclosure, immaterial governance impact.

The form demonstrates timely Section 16 compliance, detailing a tax-driven sale under Rule 10b5-1-like mechanics. Such sell-to-cover transactions are typically pre-approved and avoid potential trading-window issues. Retention of over 100k shares preserves meaningful ‘skin in the game,’ and no red flags emerge regarding unusual trading patterns. Governance impact is minimal; investors should focus on broader performance catalysts rather than this single administrative filing.

false 0000038264 0000038264 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2025

Forward Industries, Inc.

(Exact name of registrant as specified in its charter)

New York		001-34780		13-1950672
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation)		File Number)		Identification No.)

700 Veterans Memorial Hwy. Suite 100

Hauppauge, New York 11788

(Address of Principal Executive Office) (Zip Code)

(631) 547-3055

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	FORD	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 3.02 Unregistered Sales of Equity Securities.

From July 16, 2025 through July 24, 2025, the Company sold a total of 156,475 shares of common stock for total gross proceeds of $1,394,713 under that certain Securities Purchase Agreement and related Registration Rights Agreement dated May 16, 2025 (collectively, the “Agreement”), which Agreement was previously disclosed on the Company’s Current Report on Form 8-K filed on May 22, 2025. The shares were exempt from registration under Section 4(a)(2) of the Securities Act of 1933 having been sold to one accredited investor which had a pre-existing relationship with the Company and acquired the shares for investment. The triggering event for this Form 8-K filing occurred on July 24, 2025, upon completion of a sale in accordance with the Agreement.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	FORWARD INDUSTRIES, INC.
Date: July 25, 2025	By:	/s/ Kathleen Weisberg
		Name: Kathleen Weisberg
		Title: Chief Financial Officer

3

FAQ

How many NTLA shares did the CFO sell in the July 23, 2025 Form 4?

Edward J. Dulac III sold 7,462 common shares at $14.02 each.

Was the NTLA insider sale discretionary?

No. It was a mandatory sell-to-cover transaction to pay taxes on vested RSUs.

What is the CFO’s remaining NTLA share ownership?

After the sale, he directly holds 106,062 shares.

Did the Form 4 report any option exercises or derivative activity?

No. No derivative securities were acquired or disposed of in this filing.

Does the filing indicate a change in Intellia’s executive outlook?

The filing is administrative and does not signal any shift in management sentiment.